polycythemia: Abnormally high mass or concentration of red blood cells in the blood, either due to an increase in erythropoiesis or a decrease in plasma volume.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
898 |
4. Check minimum number of eventsNone |
898 |
5. Include endpointsNone |
898 |
6. Filter based on genotype QC (FinnGen only) |
874 |
Control definitions (FinnGen only)
- Control exclude
- D3_BLOODOTHER
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D75
- Name in latin
- Polycythaemia secundaria
Similar endpoints
↥List of similar endpoints to
Secondary polycythaemia
based on the number of shared cases.
Similar with more cases:
- Other diseases of blood and blood-forming organs
- Other diseases of blood and blood-forming organs, wide
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5793 | 1925 | 3795 |
| Only index persons | 4662 | 1564 | 3098 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.09 | 0.06 | 0.11 |
| Only index persons | 0.10 | 0.06 | 0.12 |
| Median age at first event (years) | |||
| Whole population | 58.75 | 60.79 | 57.65 |
| Only index persons | 57.47 | 60.07 | 56.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 874 | 305 | 569 |
| Unadjusted period prevalence (%) | 0.21 | 0.11 | 0.26 |
| Median age at first event (years) | 58.28 | 56.76 | 59.09 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 898
- Matched controls
- 8980
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D75.1
ICD-10 Finland
Secondary polycythaemia
16384.0
307.7
834
*
D45
ICD-10 Finland
Polycythaemia vera
75.6
229.3
124
19
XW000
NOMESCO Finland
Bone marrow biopsy
11.6
120.3
132
131
SPAT1074
SPAT
Venesection
38.2
86.9
54
15
TPH00
NOMESCO Finland
Phlebotomy
85.3
50.5
56
7
D75.0
ICD-10 Finland
Familial erythrocytosis
504.1
48.8
48
*
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
504.1
48.8
48
*
28900
ICD-8 Finland
Other disease of blood and blood-forming organs, Polycythaemia, secondary
+∞
48.4
46
*
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
4.4
46.6
130
334
G47.3
ICD-10 Finland
Sleep apnoea
2.8
46.4
331
1532
T90
ICPC
Diabetes non-insulin dependent
2.8
43.9
309
1413
103
Kela drug reimbursment
Diabetes, insulin-treated
2.7
43.2
341
1652
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.8
42.7
316
1480
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.7
40.3
305
1438
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
16.8
40.2
34
21
A10BA02
ATC
metformin; oral
2.6
38.9
348
1774
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.1
36.2
176
650
L01XX05
ATC
hydroxycarbamide; oral
13.0
35.1
34
27
SPAT1262
SPAT
Handing over of treatment supplies
2.7
30.9
213
942
R71
ICD-10 Finland
Abnormality of red blood cells
58.8
29.3
34
6
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
8.5
28.4
37
45
C03CA01
ATC
furosemide; systemic
2.2
26.0
307
1708
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.1
25.5
464
3040
J96.1
ICD-10 Finland
Chronic respiratory failure
5.6
24.5
47
87
R5140
NOMESCO Finland
Monitoring the use of the aid
2.7
24.2
154
649
C01AA05
ATC
digoxin; systemic
3.2
23.8
100
335
E29.1
ICD-10 Finland
Testicular hypofunction
6.5
23.7
39
62
207
Kela drug reimbursment
Chronic arrhythmias
2.5
22.7
175
806
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
2.7
22.7
134
543
E11
ICD-10 Finland
Type 2 diabetes mellitus
2.4
22.1
189
911
I10
ICD-10 Finland
Essential (primary) hypertension
2.0
21.9
582
4277
I50.9
ICD-10 Finland
Heart failure, unspecified
2.5
21.9
160
719
D75.2
ICD-10 Finland
Essential thrombocytosis
117.9
21.7
23
*
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
2.1
21.6
270
1519
C07AB07
ATC
bisoprolol; oral
2.0
21.4
471
3234
A10BH01
ATC
sitagliptin; oral
2.7
21.0
121
483
C03DA01
ATC
spironolactone; oral
2.5
20.6
140
607
E66.8
ICD-10 Finland
Other obesity
3.7
20.5
67
191
M04AA01
ATC
allopurinol; systemic
2.4
20.2
152
690
B99
ICPC
Blood/lymph/spleen disease other
49.2
20.2
24
5
R03BB04
ATC
tiotropium bromide; inhalant
2.6
19.9
127
533
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
3.1
19.7
85
289
C07AB02
ATC
metoprolol; systemic
2.2
19.1
203
1066
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.8
19.1
106
415
SPAT1249
SPAT
Treatment-related counselling outside office
1.9
18.9
351
2251
205
Kela drug reimbursment
Chronic hypertension
2.0
18.4
268
1578
A10BJ06
ATC
semaglutide; parenteral
3.3
18.4
71
225
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.1
18.2
223
1233
A10AE04
ATC
insulin glargine; parenteral
2.6
18.2
119
505
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
53.7
18.0
21
*
A10BK03
ATC
empagliflozin; oral
2.5
17.1
121
532
E66.01
ICD-10 Finland
Obesity due to excess calories
2.7
16.9
96
380
R06.0
ICD-10 Finland
Dyspnoea
1.9
16.6
259
1553
C08CA01
ATC
amlodipine; oral
1.8
16.6
365
2444
XG466
NOMESCO Finland
Sleep oxymetry
3.8
16.5
52
144
J44
ICD-10 Finland
Other chronic obstructive pulmonary disease
5.1
16.5
35
71
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.2
15.6
140
682
E66.00
ICD-10 Finland
Metabolic syndrome
3.0
15.5
72
255
B01AA03
ATC
warfarin; systemic
2.0
15.4
190
1047
346
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
2.9
15.3
73
263
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.1
15.2
163
852
A10BK01
ATC
dapagliflozin; oral
2.6
14.7
87
351
D58.2
ICD-10 Finland
Other haemoglobinopathies
+∞
14.6
14
*
E66.2
ICD-10 Finland
Extreme obesity with alveolar hypoventilation
6.7
14.5
23
35
R79.8
ICD-10 Finland
Other specified abnormal findings of blood chemistry
17.3
14.3
22
13
J44.1
ICD-10 Finland
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
3.5
14.2
49
145
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.3
14.1
117
551
R03AC02
ATC
salbutamol; inhalant
1.7
14.0
476
3560
201
Kela drug reimbursment
Chronic cardiac insufficiency
3.0
13.8
63
221
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
3.5
13.7
47
138
121
Kela drug reimbursment
Severe hypofunction of sexual glands
5.2
13.7
28
55
C09AA02
ATC
enalapril; systemic
1.9
13.6
188
1075
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
2.9
13.5
65
235
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
2.2
13.0
125
625
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.5
12.8
81
338
WX723
NOMESCO Finland
CPAP therapy
3.0
12.7
57
198
I48.9
ICD-10 Finland
Atrial fibrillation and atrial flutter, unspecified
2.7
12.7
73
290
2890X
ICD-9 Finland
Other diseases of blood and blood-forming organs, Polycythaemia, secondary[ERYTHROCYTOSIS SECUNDARIA, NUD]
+∞
12.5
12
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
1.9
12.5
180
1041
J44.9
ICD-10 Finland
Chronic obstructive pulmonary disease, unspecified
2.9
12.5
60
217
N02AX02
ATC
tramadol; systemic, rectal
1.7
12.4
395
2871
M10.9
ICD-10 Finland
Gout, unspecified
2.5
12.2
78
326
A10BJ02
ATC
liraglutide; parenteral
3.6
12.2
41
119
I50.0
ICD-10 Finland
Congestive heart failure
2.5
12.2
78
327
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
3.0
12.1
55
193
E66.9
ICD-10 Finland
Obesity, unspecified
3.5
11.8
41
122
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.8
11.7
223
1404
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
2.8
11.5
58
215
Y28
ICPC
Limited function/disability (Y)
17.3
11.2
17
10
A10AB05
ATC
insulin aspart; parenteral
2.4
11.2
81
359
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
1.8
11.1
177
1054
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
3.6
11.1
37
107
H02AB06
ATC
prednisolone; systemic
1.6
11.0
410
3073
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
43.9
10.9
13
*
WX780
NOMESCO Finland
Remote monitoring CPAP
2.7
10.9
57
216
N06AX11
ATC
mirtazapine; oral
1.7
10.8
289
1991
ZXE00
NOMESCO Finland
One hour or less
1.6
10.8
327
2325
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.7
10.8
293
2026
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.0
10.6
135
747
SPAT1377
SPAT
Polysomnography
3.2
10.4
40
127
N06AX12
ATC
bupropion; oral
2.5
10.4
68
288
N07BA03
ATC
varenicline; oral
2.8
10.4
54
204
SPAT1305
SPAT
Counselling and guidance related to physical exercise
2.2
10.0
85
404
C02AC05
ATC
moxonidine; oral
2.7
9.9
55
215
J45.9
ICD-10 Finland
Asthma, unspecified
1.8
9.8
159
949
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
1.8
9.7
153
905
A02BC02
ATC
pantoprazole; systemic
1.6
9.7
581
4809
E83.1
ICD-10 Finland
Disorders of iron metabolism
13.5
9.7
16
12
J45.8
ICD-10 Finland
Mixed asthma
3.6
9.6
31
88
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
1.8
9.6
156
933
TFP20
NOMESCO Finland
Cardiodefibrillation
2.2
9.4
77
360
D70.82
ICD-10 Finland
Drug-induced neutropenia
+∞
9.4
9
*
N06AB10
ATC
escitalopram; oral
1.8
9.4
166
1017
212
Kela drug reimbursment
Gout
4.4
9.4
23
53
SPAT1263
SPAT
Sampling
1.6
9.3
340
2507
Z01.8
ICD-10 Finland
Other specified special examinations
1.7
9.2
191
1223
SPAT1225
SPAT
Implementation of podiatry rehabilitation plan
3.4
9.1
32
96
I27.9
ICD-10 Finland
Pulmonary heart disease, unspecified
15.8
9.0
14
9
R79.9
ICD-10 Finland
Abnormal finding of blood chemistry, unspecified
10.2
9.0
17
17
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
37.1
9.0
11
*
R07.4
ICD-10 Finland
Chest pain, unspecified
1.6
8.9
245
1686
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
1.9
8.8
109
595
L28
ICPC
Limited function/disability (L)
1.8
8.8
141
837
C09AA05
ATC
ramipril; oral
1.6
8.8
233
1590
C03EA01
ATC
hydrochlorothiazide and potassium-sparing agents; oral
1.9
8.8
123
701
SPAT1254
SPAT
Administration of medicine
1.9
8.7
120
680
SPAT1260
SPAT
Consultation of another employee
1.8
8.6
146
881
C10AA01
ATC
simvastatin; oral
1.5
8.5
363
2760
C08CA02
ATC
felodipine; oral
2.1
8.5
84
424
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
2.6
8.4
47
185
Q21.81
ICD-10 Finland
Eisenmenger's syndrome
+∞
8.3
8
*
SPAT1148
SPAT
Treatment of chronic ulcer or burn
1.9
8.3
119
683
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
1.6
8.3
240
1671
SPAT1309
SPAT
Guidance related to psychoactive substances / risk behaviour
3.2
8.1
31
98
R53
ICD-10 Finland
Malaise and fatigue
1.6
8.1
197
1311
TPH00, ,
SPAT
33.7
8.1
10
*
C09CA01
ATC
losartan; oral
1.6
8.1
225
1550
SPAT1281
SPAT
Other administrative function
2.2
8.0
70
337
I50.1
ICD-10 Finland
Left ventricular failure
2.5
8.0
50
208
A10BB12
ATC
glimepiride; oral
2.2
7.9
68
325
Z72.0
ICD-10 Finland
Tobacco use
3.2
7.9
31
100
F32.9
ICD-10 Finland
Depressive episode, unspecified
1.9
7.9
100
551
I11.9
ICD-10 Finland
Hypertensive heart disease without (congestive) heart failure
2.6
7.9
44
173
K76.0
ICD-10 Finland
Fatty (change of) liver, not elsewhere classified
3.1
7.8
32
106
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
2.1
7.8
78
396
R03AK06
ATC
salmeterol and fluticasone; inhalant
1.8
7.6
124
739
P06
ICPC
Sleep disturbance
1.9
7.5
100
561
K99
ICPC
Cardiovascular disease other
3.3
7.4
28
88
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.0
7.4
82
432
I48.1
ICD-10 Finland
Persistent atrial fibrillation
2.7
7.4
40
155
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.5
7.3
329
2507
I42.0
ICD-10 Finland
Dilated cardiomyopathy
3.0
7.3
32
110
B04
ICPC
Blood symptom/complaint
11.0
7.3
13
12
OAB50, ,
SPAT
2.3
7.3
53
236
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
1.6
7.2
201
1379
J01MA02
ATC
ciprofloxacin; systemic
1.5
7.2
321
2439
R03AL06
ATC
olodaterol and tiotropium bromide; inhalant
3.5
7.2
24
70
M54.5
ICD-10 Finland
Low back pain
1.5
7.1
289
2154
J01AA02
ATC
doxycycline; systemic
1.5
7.1
656
5747
I27.2
ICD-10 Finland
Other secondary pulmonary hypertension
10.1
7.0
13
13
H02AB09
ATC
hydrocortisone; systemic
3.6
7.0
23
66
WX110
NOMESCO Finland
Infiltration anesthesia
1.5
6.9
583
4999
M79.6
ICD-10 Finland
Pain in limb
1.5
6.9
326
2504
A46
ICD-10 Finland
Erysipelas
1.7
6.9
130
808
N05CF02
ATC
zolpidem; oral
1.7
6.9
140
888
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
2.8
6.8
34
126
D75.8
ICD-10 Finland
Other specified diseases of blood and blood-forming organs
40.4
6.8
8
*
WX402
NOMESCO Finland
General anaesthesia
1.6
6.7
168
1122
M10
ICD-10 Finland
Gout
2.4
6.7
46
200
A12BA01
ATC
potassium chloride; oral
2.6
6.7
38
151
J01DB01
ATC
cefalexin; oral
1.5
6.7
699
6239
N02AJ06
ATC
codeine and paracetamol; systemic
1.5
6.6
352
2759
XFE00
NOMESCO Finland
Epicardial ultrasonography
3.2
6.6
26
84
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
5.5
6.6
18
33
F17.29
ICD-10 Finland
Addiction caused by tobacco UNS
3.6
6.6
21
59
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
1.9
6.6
87
486
A10BH02
ATC
vildagliptin; oral
3.4
6.6
23
69
GX2D5
NOMESCO Finland
Sleep oximetry
8.8
6.6
13
15
A10BH05
ATC
linagliptin; oral
2.3
6.5
46
202
R03BA05
ATC
fluticasone; inhalant
1.7
6.5
142
916
SPAT1307
SPAT
Psychosocial counselling and guidance
2.5
6.5
38
153
160
Kela drug reimbursment
exenatide
3.1
6.5
26
85
C09DA01
ATC
losartan and diuretics; oral
1.8
6.5
94
541
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
2.4
6.5
41
172
C03AA03
ATC
hydrochlorothiazide; oral
2.0
6.4
73
388
K80.2
ICD-10 Finland
Calculus of gallbladder without cholecystitis
1.8
6.4
92
528
R03AL03
ATC
vilanterol and umeclidinium bromide; inhalant
3.8
6.4
19
51
H03AA01
ATC
levothyroxine sodium; systemic
1.6
6.3
156
1039
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.5
6.3
209
1489
D70.89
ICD-10 Finland
Neutropenic splenomegaly
26.9
6.2
8
*
QXB99
NOMESCO Finland
Other procedure to treat skin wound, unspecified location
3.7
6.2
19
52
I50
ICD-10 Finland
Heart failure
2.8
6.2
29
104
XF600
NOMESCO Finland
Bloodpressure measurement
2.1
6.2
54
260
R52.9
ICD-10 Finland
Pain, unspecified
1.9
6.2
80
444
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
3.4
6.2
21
62
Z02.7
ICD-10 Finland
Issue of medical certificate
2.1
6.1
60
302
N06AB06
ATC
sertraline; oral
1.8
6.1
88
505
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
1.6
6.1
151
1005
A10AE05
ATC
insulin detemir; parenteral
2.2
6.1
50
235
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
3.2
6.0
23
73
EBA00
NOMESCO Finland
Extraction of tooth
1.5
6.0
287
2197
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
362
78
77.08
307.65
1.1
1.0
—
—
—
0
0
435
107
77.91
307.65
1.4
1.2
15.16
52.25
u/l
1.20
382
93
270
750
4.72
91.17
2.9
4.0
235.54
249.96
u/l
0.54
250
707
302
933
4.37
88.47
2.2
2.5
25.62
23.48
%
1.56
270
800
307
985
4.22
85.01
2.2
2.4
2.57
2.31
g/l
13.03
284
913
311
1082
3.87
75.60
2.4
2.5
15.88
13.41
umol/l
5.62
288
1006
611
3345
3.59
71.07
6.9
6.0
26.57
27.32
%
1.00
582
3145
675
4006
3.76
67.47
9.6
9.0
4.63
4.18
e9/l
4.91
605
3505
595
3295
3.39
65.98
6.5
5.8
58.07
57.58
%
0.50
563
3099
223
753
3.61
54.75
2.1
2.6
1.82
1.78
%
0.28
193
676
171
550
3.61
44.55
2.5
2.6
94.85
69.74
e9/l
11.05
131
427
80
152
5.68
40.80
5.7
4.3
3.28
2.59
mmol/l
0.76
56
102
394
2148
2.49
37.93
3.7
3.3
76.53
233.29
mg/l
1.45
276
1438
475
2832
2.44
37.32
3.2
2.7
146.98
148.57
ug/l
0.04
439
2596
569
3685
2.49
37.05
6.7
6.5
14.12
11.62
umol/l
5.27
556
3504
361
1928
2.46
35.91
3.2
2.6
2679.82
6076.62
umol/l
1.05
320
1704
402
2259
2.41
35.62
4.6
3.9
13.22
9.02
mg/mmol
0.94
263
1481
397
2289
2.32
32.35
3.8
3.2
8.20
8.08
mmol/l
0.19
321
1921
724
5452
2.69
30.98
9.3
7.6
81.90
78.22
u/l
1.01
694
5127
64
128
5.31
30.76
2.9
3.3
58.17
57.34
%
0.18
64
128
61
124
5.20
28.77
2.7
3.0
4.56
4.31
e9/l
0.39
61
124
456
3000
2.06
24.47
5.1
5.0
35.77
35.66
g/l
0.16
421
2793
467
3112
2.04
24.05
7.4
6.4
1.21
1.21
mmol/l
0.39
435
2831
46
86
5.58
23.75
1.8
2.0
33.24
33.10
pg
0.06
46
86
499
3423
2.03
23.50
7.7
7.1
1.21
1.21
mmol/l
0.14
395
2923
135
547
2.73
22.85
3.7
3.7
1.22
1.23
mmol/l
0.19
121
480
578
4204
2.05
22.81
6.7
5.0
7.18
6.77
mmol/l
4.25
568
3969
348
2130
2.03
22.24
4.0
3.3
124.65
89.23
e6/l
0.24
277
1649
71
201
3.75
21.91
1.7
1.4
6.12
7.92
u/l
0.76
55
164
490
3401
1.97
21.63
21.9
14.2
1.32
1.27
inr
0.62
190
984
60
152
4.16
21.59
3.2
2.4
20.50
16.34
%
7.30
34
81
335
2047
2.02
21.31
3.9
3.0
1488.80
1352.36
ng/l
0.28
278
1732
256
1451
2.07
19.80
3.4
2.6
4.15
4.21
e6/l
0.04
227
1305
165
791
2.33
19.39
4.4
2.2
13.66
13.34
nmol/l
0.17
150
720
316
1944
1.97
19.32
3.9
3.2
0.52
0.52
e6/l
0.00
251
1480
162
813
2.21
16.91
2.6
2.8
9.42
8.84
umol/l
0.15
144
716
643
5104
1.91
16.79
4.6
3.5
15.20
14.82
pmol/l
3.16
579
4618
108
460
2.53
16.35
4.0
3.5
2.78
1.82
mmol/l
1.74
81
337
650
5204
1.90
16.19
4.4
3.9
7.23
11.73
mm/h
17.48
606
4792
353
2359
1.82
16.02
3.8
3.5
34.28
34.22
u/l
0.01
343
2230
362
2446
1.80
15.77
4.6
3.7
106.40
93.33
e6/l
0.15
284
1763
370
2538
1.78
15.17
4.0
3.2
—
—
—
0
0
174
936
2.07
15.06
6.0
6.2
1.05
1.03
mmol/l
0.38
166
866
67
238
2.96
14.36
2.8
1.9
189.94
213.72
pmol/l
0.92
67
225
158
846
2.05
13.77
7.9
9.0
1.93
1.12
mmol/l
1.24
126
675
50
153
3.40
13.73
2.2
2.3
164.18
131.71
g/l
10.52
45
114
144
749
2.10
13.55
4.8
3.2
—
—
—
0
0
273
1760
1.79
13.50
4.3
4.0
83.08
89.46
%
3.28
263
1724
126
624
2.19
13.44
2.8
2.0
345.14
370.99
nmol/l
0.90
120
578
393
2817
1.70
13.27
4.9
3.5
23.30
44.82
ng/l
4.72
307
2007
327
2238
1.73
13.03
3.1
2.6
50.68
59.99
u/l
3.21
300
2093
57
196
3.04
12.94
2.0
3.0
1.45
1.56
mg/l
0.47
46
178
244
1556
1.78
12.35
2.0
1.7
0.96
1.19
mg/l
1.16
183
1200
26
53
5.02
12.21
1.5
1.7
18.03
19.15
nmol/l
0.23
26
48
191
1141
1.86
11.94
4.1
3.5
0.82
0.82
mmol/l
0.14
181
1079
273
1815
1.72
11.87
4.4
3.7
0.00
0.01
estimate
0.69
114
601
55
196
2.92
11.74
1.7
1.7
230.14
276.47
mu/l
0.84
50
184
734
6338
1.87
11.69
5.6
4.2
1.91
2.11
mu/l
0.52
658
5763
714
6139
1.80
11.20
24.3
16.7
15.80
14.91
%
2.90
707
6039
445
3396
1.62
11.11
4.1
3.5
0.00
0.01
estimate
0.50
115
593
762
6700
1.91
10.89
8.4
5.7
42.90
40.03
mmol/mol
8.97
695
6232
188
1150
1.80
10.79
2.2
1.8
—
—
—
0
0
774
6850
1.94
10.70
20.4
12.8
78.18
81.71
ml/min/173m2
4.50
682
5683
439
3360
1.60
10.68
5.2
4.7
0.00
0.00
estimate
-0.00
129
634
440
3373
1.60
10.61
4.1
3.4
0.00
0.00
estimate
0.50
131
671
798
7159
2.03
10.26
19.7
14.0
20.10
25.03
mg/l
5.08
698
5664
248
1665
1.68
10.15
2.6
2.1
5.22
3.02
mg/l
7.15
215
1415
37
118
3.23
9.56
1.7
1.8
—
—
—
0
0
73
333
2.30
9.46
3.3
3.5
4.63
4.60
pmol/l
0.10
62
300
121
672
1.93
9.35
2.1
2.3
0.22
0.21
g/l
0.62
116
628
101
535
2.00
8.94
2.8
2.9
64.97
66.58
g/l
1.14
92
487
351
2633
1.55
8.81
4.1
3.6
—
—
—
0
0
52
211
2.55
8.70
2.7
4.0
48.90
89.52
mg/l
0.71
38
171
52
211
2.55
8.70
2.7
4.0
36.37
32.35
mg/l
0.30
39
174
27
75
3.68
8.61
2.0
1.8
—
—
—
0
0
810
7393
1.98
8.57
24.6
16.4
139.64
139.71
mmol/l
0.42
793
7211
270
1920
1.58
8.52
1.7
1.7
1.80
1.45
mmol/l
3.65
201
1620
78
382
2.14
8.51
7.8
11.8
24.26
24.57
mmol/l
0.34
78
374
354
2703
1.51
7.98
2.6
2.2
72.68
75.67
nmol/l
1.29
319
2406
582
4922
1.52
7.96
3.8
3.2
64.35
53.32
u/l
1.72
536
4614
809
7415
1.92
7.93
25.1
16.5
3.98
3.99
mmol/l
0.27
792
7227
25
72
3.54
7.58
1.4
1.5
0.24
0.30
nmol/l
0.35
19
56
68
333
2.13
7.43
5.2
3.9
24.15
24.21
mmol/l
0.05
68
325
113
660
1.81
7.43
4.7
3.6
2.14
2.04
mmol/l
0.11
98
541
528
4430
1.47
7.11
5.5
4.2
221.18
1374.94
e6/l
0.53
11
65
16
24
6.77
6.83
1.6
2.7
199.25
203.00
u/l
0.09
16
24
302
2293
1.48
6.74
3.5
3.4
2.36
2.35
mmol/l
1.18
264
2017
152
995
1.64
6.61
2.0
1.9
1.52
1.52
%
0.00
131
877
782
7174
1.70
6.58
5.4
4.4
1.19
1.40
mmol/l
45.73
711
6638
287
2168
1.48
6.53
2.3
2.1
267.53
270.14
u/l
0.01
259
2045
785
7220
1.69
6.40
5.4
4.4
4.37
4.62
mmol/l
10.42
720
6717
796
7349
1.73
6.39
6.1
4.9
2.66
2.76
mmol/l
2.81
723
6799
759
6929
1.62
6.29
4.9
4.0
1.64
1.35
mmol/l
13.62
682
6393
83
464
1.87
6.28
4.5
4.2
97.60
91.61
ng/l
0.26
68
413
35
141
2.54
6.01
3.7
3.0
0.81
0.91
nmol/l
0.43
28
111
39
166
2.41
5.97
1.7
1.7
—
—
—
0
0
26
91
2.91
5.82
1.6
1.7
—
—
—
0
0
204
1470
1.50
5.77
1.9
1.7
85161720.68
26080300.52
pmol/l
0.47
155
1227
21
65
3.28
5.75
2.4
2.2
589.08
644.82
ml
0.37
13
39
352
2814
1.41
5.75
1.9
1.9
89.67
94.40
pmol/l
1.19
196
1490
38
164
2.38
5.65
1.7
1.7
—
—
—
0
0
125
814
1.62
5.52
2.1
1.8
—
—
—
0
0
124
809
1.62
5.44
2.0
1.8
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
48
235
2.10
5.31
4.1
2.6
0.38
0.32
u/ml
0.73
32
119
26
97
2.73
5.21
2.0
1.6
—
—
—
0
0
819
7695
1.73
5.20
14.3
10.2
34.34
28.59
u/l
4.27
789
7433
761
7026
1.54
5.18
6.0
4.5
6.51
6.01
mmol/l
11.96
685
6424
8
6
13.44
5.08
1.0
1.0
—
—
—
0
0
22
77
2.90
4.95
1.8
1.3
168.93
163.70
pmol/l
0.05
22
77
16
37
4.38
4.95
1.4
1.6
—
—
—
0
0
93
578
1.68
4.93
3.4
3.0
293.67
190.67
ng/l
1.49
81
522
30
125
2.45
4.85
1.4
1.4
122.33
107.22
u/ml
—
6
23
171
1237
1.47
4.68
3.0
3.2
2.48
2.44
mmol/l
2.94
139
1089
15
36
4.22
4.53
1.4
1.6
—
—
—
0
0
17
54
3.19
4.50
1.9
1.5
—
—
—
0
0
15
44
3.45
4.48
1.4
1.5
—
—
—
0
0
41
203
2.07
4.44
2.1
2.3
68.56
112.21
ug/min
0.60
21
121
171
1251
1.45
4.40
1.3
1.4
2.73
2.55
g/l
0.34
118
788
20
73
2.78
4.20
1.1
1.1
—
—
—
0
0
165
1214
1.44
4.11
3.5
2.8
1.02
0.96
e6/l
0.07
100
705
31
142
2.23
4.09
1.2
1.2
—
—
—
0
0
24
98
2.49
4.08
1.2
1.1
—
—
—
0
0
23
95
2.46
3.83
1.3
1.5
—
—
—
0
0
152
1116
1.44
3.82
2.7
2.1
32.49
29.72
s
3.34
147
1086
28
127
2.24
3.80
1.1
1.1
260.22
63.39
iu/ml
—
9
28
39
202
1.97
3.78
1.7
1.5
292.91
276.81
ug/g
0.16
22
123
27
122
2.25
3.70
1.6
1.6
—
—
—
0
0
9
16
5.67
3.66
1.0
1.1
—
—
—
0
0
154
1144
1.42
3.63
3.6
2.9
3.03
1.64
e6/l
0.59
87
639
31
150
2.10
3.61
1.3
1.3
10.69
12.40
e6/l
0.08
26
116
29
137
2.15
3.58
1.2
1.2
312.55
287.60
u/ml
0.16
20
81
30
144
2.12
3.56
1.6
1.9
3.07
5.64
iu/l
1.24
11
44
8
13
6.20
3.50
1.3
1.4
—
—
—
0
0
36
187
1.96
3.48
1.1
1.2
—
—
—
0
0
23
100
2.33
3.45
1.6
1.2
1.80
4.50
u/ml
—
5
34
47
268
1.80
3.43
5.3
4.1
1.35
1.39
mmol/l
0.14
47
261
35
182
1.96
3.38
2.8
3.0
0.00
0.00
g/l
-0.00
35
168
39
211
1.89
3.36
1.6
1.6
—
—
—
0
0
35
184
1.94
3.28
2.8
3.0
0.00
0.00
g/l
-0.00
35
169
15
56
2.71
3.07
18.8
17.2
1166.73
1481.02
nmol/l
1.06
15
56
36
196
1.87
3.06
3.0
3.0
0.02
0.03
g/l
0.09
36
181
178
1393
1.35
3.04
1.2
1.2
1.08
1.89
u/ml
0.74
56
397
23
107
2.18
2.98
1.3
1.5
—
—
—
0
0
95
670
1.47
2.96
2.3
2.4
30.55
39.72
u/l
0.74
83
574
12
38
3.19
2.86
1.3
1.1
—
—
—
0
0
67
447
1.54
2.74
1.8
1.6
—
—
—
0
0
36
204
1.80
2.73
3.0
2.8
37.68
37.58
g/l
0.03
36
180
40
234
1.74
2.73
2.8
2.7
10.34
10.58
g/l
0.14
40
209
23
114
2.04
2.58
1.6
1.7
—
—
—
0
0
23
114
2.04
2.58
1.6
1.7
—
—
—
0
0
383
3367
1.24
2.57
4.6
4.5
1.84
2.35
ug/l
1.77
342
3027
172
1373
1.31
2.56
5.0
3.7
1726.02
426.36
ng/l
0.41
134
1088
42
256
1.67
2.50
2.7
2.6
3.60
3.61
g/l
0.00
42
232
42
256
1.67
2.50
2.7
2.6
—
—
—
0
0
42
256
1.67
2.50
2.7
2.6
7.47
7.35
g/l
0.21
42
232
15
63
2.40
2.47
1.4
1.1
—
—
—
0
0
47
297
1.61
2.44
4.2
4.0
24.96
24.90
mmol/l
0.06
42
277
159
1268
1.31
2.38
1.9
1.7
1150.77
1167.66
nmol/l
0.08
119
954
7
17
4.14
2.36
1.0
1.5
—
—
—
0
0
368
3249
1.22
2.31
2.8
2.6
—
—
—
0
0
39
239
1.66
2.29
2.8
2.7
3.10
2.99
g/l
0.33
39
215
28
156
1.82
2.28
1.5
1.5
—
—
—
0
0
20
100
2.02
2.22
1.7
1.2
4.27
6.48
u/ml
0.36
11
46
16
73
2.21
2.22
1.3
1.3
—
—
—
0
0
5
9
5.58
2.21
1.6
1.4
60.60
103.78
ng/l
—
5
9
29
166
1.77
2.17
1.2
1.4
128.12
214.84
miu/ml
—
10
75
45
294
1.56
2.07
1.9
1.9
0.77
2.37
ug/l
0.92
39
257
20
103
1.96
2.06
1.3
1.1
0.26
1.83
u/ml
1.02
11
56
26
147
1.79
2.04
3.3
3.7
9.95
25.11
mg/l
4.46
17
91
828
8026
1.41
2.02
32.7
20.5
46.75
40.88
%
84.88
788
7507
828
8028
1.40
2.00
32.4
20.3
243.90
244.42
e9/l
0.06
818
7830
828
8032
1.40
1.95
32.5
20.3
5.29
4.57
e12/l
129.57
813
7814
192
1607
1.25
1.95
1.5
1.5
18.54
20.13
nmol/l
0.93
168
1352
6
16
3.77
1.93
3.7
1.5
1.17
1.23
mmol/l
—
6
16
9
33
2.74
1.93
1.0
1.0
—
—
—
0
0
828
8034
1.39
1.93
32.8
20.4
156.67
138.25
g/l
107.68
818
7913
28
165
1.72
1.93
1.4
1.2
—
—
—
0
0
14
65
2.17
1.88
1.0
1.1
—
—
u/ml
—
0
0
12
52
2.33
1.88
1.1
1.1
46.25
44.96
mg/l
—
6
44
16
79
2.04
1.86
2.9
3.2
5.21
5.35
nmol/l
0.02
16
79
132
1069
1.28
1.77
1.5
1.4
—
—
—
0
0
14
67
2.11
1.76
1.1
2.0
—
—
—
0
0
45
306
1.50
1.76
1.0
1.0
—
—
—
0
0
67
492
1.39
1.76
1.5
1.6
—
—
—
0
0
15
74
2.04
1.75
1.2
1.9
—
—
—
0
0
55
390
1.44
1.75
1.3
1.2
149.68
144.94
iu/ml
0.02
15
156
19
103
1.86
1.72
2.2
3.1
—
2811.44
—
0
9
10
40
2.52
1.67
1.0
1.1
0.92
1.09
u/l
—
5
19
15
76
1.99
1.65
1.0
1.1
—
—
—
0
0
8
32
2.51
1.60
2.5
3.0
47612.50
40906.25
ug/l
—
8
32
14
70
2.02
1.59
2.8
2.3
—
—
—
0
0
10
43
2.34
1.59
1.0
1.0
—
—
—
0
0
44
306
1.46
1.57
1.8
2.0
42.97
38.78
u/l
0.58
38
267
11
51
2.17
1.51
1.1
1.2
—
—
—
0
0
15
79
1.91
1.50
1.8
1.6
—
—
—
0
0
15
79
1.91
1.50
1.8
1.6
—
—
—
0
0
41
285
1.46
1.48
2.3
1.9
—
—
—
0
0
301
2699
1.17
1.46
4.1
3.9
22.64
21.01
%
1.08
136
1186
5
16
3.14
1.44
1.0
1.9
50.80
89.67
%
—
5
9
5
16
3.14
1.44
1.0
1.1
44.00
98.78
%
—
5
9
9
39
2.32
1.43
1.6
3.6
65.67
81.92
nmol/l
—
9
39
72
556
1.32
1.41
1.9
1.9
—
—
—
0
0
7
29
2.42
1.39
1.1
1.2
—
—
—
0
0
91
728
1.28
1.38
3.8
4.5
4.46
25.73
ug/l
1.21
83
614
0
37
0.00
1.34
0.0
1.2
—
—
—
0
0
84
668
1.28
1.34
2.6
2.4
9.97
7.74
ug/l
0.23
71
596
12
61
1.98
1.33
1.3
1.5
72.00
81.49
umol/l
0.95
12
61
37
259
1.45
1.31
2.2
1.7
—
—
—
0
0
8
36
2.23
1.24
1.1
1.8
—
—
—
0
0
8
36
2.23
1.24
1.1
1.8
—
—
—
0
0
12
63
1.92
1.23
1.1
1.7
—
—
—
0
0
12
63
1.92
1.23
1.1
1.7
—
—
—
0
0
12
63
1.92
1.23
1.1
1.7
—
—
—
0
0
8
37
2.17
1.21
1.1
1.2
35.08
24.08
u/l
—
8
37
8
37
2.17
1.21
1.1
1.2
117.69
86.95
u/l
—
8
37
6
26
2.32
1.19
2.8
4.0
—
—
—
0
0
468
4395
1.14
1.12
3.0
2.8
—
—
—
0
0
8
40
2.01
1.12
2.6
3.1
—
—
—
0
0
55
704
0.77
1.12
1.8
1.8
—
—
—
0
0
27
185
1.47
1.09
1.3
1.3
—
—
—
0
0
8
41
1.96
1.09
1.5
1.4
—
—
—
0
0
7
32
2.20
1.08
2.0
2.7
70.57
101.78
%
—
7
32
76
617
1.25
1.06
2.0
2.0
—
—
—
0
0
9
47
1.92
1.02
1.0
1.0
—
—
—
0
0
9
49
1.85
0.98
1.2
1.4
—
24.43
—
0
7
54
426
1.28
0.97
1.6
1.4
—
—
—
0
0
9
50
1.81
0.96
1.2
1.2
—
—
—
0
0
12
69
1.75
0.96
1.1
1.1
—
—
—
0
0
20
133
1.52
0.95
1.8
1.3
—
—
—
0
0
20
133
1.52
0.95
1.8
1.3
—
—
—
0
0
7
37
1.90
0.94
1.1
1.1
179.34
265.68
iu/ml
—
7
37
17
109
1.57
0.94
1.1
1.3
—
—
—
0
0
13
78
1.68
0.92
1.0
1.1
—
—
—
0
0
8
42
1.91
0.88
1.0
1.2
—
—
—
0
0
33
247
1.35
0.86
2.4
3.1
—
—
—
0
0
11
64
1.73
0.86
1.0
1.1
—
—
—
0
0
11
64
1.73
0.86
3.2
2.4
—
—
—
0
0
28
204
1.38
0.86
1.3
1.4
—
—
—
0
0
8
44
1.83
0.86
2.0
2.4
—
—
—
0
0
8
137
0.58
0.84
1.4
1.4
—
—
—
0
0
43
337
1.29
0.83
1.1
1.3
—
—
—
0
0
12
73
1.65
0.82
1.1
1.2
54.41
48.90
u/l
0.36
12
67
37
287
1.30
0.78
2.2
3.8
140.17
4869.25
u/ml
0.75
30
244
25
183
1.38
0.76
1.2
1.1
—
—
—
0
0
5
26
1.93
0.70
1.0
1.0
2023.40
1562.04
miu/ml
—
5
26
13
86
1.52
0.66
1.2
1.1
—
—
—
0
0
11
70
1.58
0.65
1.1
1.4
11.16
26.14
u/l
1.68
11
57
5
29
1.73
0.64
1.0
2.0
—
—
—
0
0
5
29
1.73
0.64
1.0
2.0
—
—
—
0
0
77
886
0.86
0.63
5.0
4.5
26.86
31.19
%
3.88
58
606
27
208
1.31
0.62
1.0
1.1
—
—
—
0
0
5
30
1.67
0.61
1.0
1.9
—
—
—
0
0
27
210
1.29
0.59
1.0
1.1
—
—
—
0
0
8
53
1.51
0.58
1.4
1.1
—
—
—
0
0
8
53
1.51
0.58
1.4
1.1
—
—
—
0
0
6
35
1.72
0.57
1.0
1.2
—
—
—
0
0
212
1970
1.10
0.57
3.0
2.8
0.72
0.73
ug/l
0.12
139
1215
8
54
1.49
0.57
1.4
1.1
—
—
—
0
0
8
54
1.49
0.57
1.4
1.1
—
—
—
0
0
8
54
1.49
0.57
1.4
1.1
—
—
—
0
0
22
167
1.33
0.57
1.2
1.2
—
1.78
—
0
9
6
36
1.67
0.56
1.8
1.3
—
—
—
0
0
8
55
1.46
0.56
1.0
1.2
—
—
—
0
0
127
1150
1.12
0.56
1.3
1.3
17.37
31.29
iu/ml
3.29
42
359
12
170
0.70
0.53
1.2
1.4
—
—
—
0
0
18
134
1.35
0.53
1.2
1.1
—
—
—
0
0
21
161
1.31
0.52
1.1
1.6
—
—
—
0
0
9
65
1.39
0.50
2.6
1.9
—
—
—
0
0
6
41
1.47
0.50
1.0
1.2
13.00
12.50
u/l
—
6
34
12
85
1.42
0.47
1.2
1.5
68.00
61.79
%
—
5
58
30
248
1.22
0.43
2.5
2.7
22.20
47.64
u/ml
1.26
30
236
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
118
1087
1.10
0.40
1.2
1.3
7.94
10.00
u/ml
0.16
50
441
5
35
1.43
0.39
1.0
1.8
—
—
—
0
0
5
35
1.43
0.39
1.0
1.8
—
—
—
0
0
23
189
1.22
0.36
1.4
1.6
15869.37
17880.10
e6/l
0.14
16
137
6
43
1.40
0.35
1.0
1.2
60.83
71.89
u/l
—
6
37
179
1692
1.07
0.34
2.6
2.4
—
—
—
0
0
160
1507
1.08
0.34
4.1
3.7
1.01
1.02
kg/l
1.04
31
214
24
200
1.21
0.34
1.7
1.6
—
—
—
0
0
13
100
1.30
0.33
1.1
1.1
—
—
—
0
0
6
47
1.28
0.32
1.2
1.3
—
—
—
0
0
6
47
1.28
0.32
1.2
1.3
—
—
—
0
0
61
666
0.91
0.27
1.3
1.4
—
—
—
0
0
5
71
0.70
0.26
1.6
2.7
—
—
—
0
0
9
76
1.19
0.24
3.0
4.0
—
—
—
0
0
25
217
1.16
0.24
1.3
1.3
—
—
—
0
0
20
172
1.17
0.22
11.3
9.6
104.70
105.61
mmol/l
0.43
20
155
5
42
1.19
0.21
1.0
1.3
—
—
—
0
0
5
42
1.19
0.21
1.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.9
—
76.91
—
0
10
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
0.57
—
0
8
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
6
48
1.25
0.20
1.2
1.1
—
—
—
0
0
6
49
1.23
0.20
1.7
1.4
—
—
—
0
0
14
119
1.18
0.17
1.1
1.2
—
1.05
—
0
8
15
131
1.15
0.14
1.1
1.2
—
—
—
0
0
29
267
1.09
0.13
2.2
1.8
—
—
—
0
0
11
126
0.87
0.11
1.1
1.4
—
—
—
0
0
61
585
1.05
0.10
2.2
2.4
56.08
67.50
ml/min/173m2
1.33
25
217
5
45
1.11
0.10
1.0
1.3
1.40
1.54
g/l
—
5
45
26
243
1.07
0.09
2.0
2.1
—
—
—
0
0
13
118
1.10
0.07
1.2
1.5
—
—
—
0
0
9
102
0.88
0.06
1.1
1.5
—
—
—
0
0
9
102
0.88
0.06
1.1
1.5
—
—
—
0
0
9
103
0.87
0.06
1.1
1.5
—
—
—
0
0
20
211
0.95
0.04
1.5
1.6
0.02
0.13
iu/ml
—
6
41
16
154
1.04
0.00
1.9
1.6
—
—
—
0
0
20
202
0.99
0.00
1.4
2.0
—
—
—
0
0
87
874
0.99
0.00
11.2
6.8
—
—
—
0
0
10
103
0.97
0.00
1.2
1.5
—
—
—
0
0
10
103
0.97
0.00
1.2
1.5
—
—
—
0
0
10
101
0.99
0.00
1.2
1.5
—
—
—
0
0
11
105
1.05
0.00
1.8
1.5
—
—
—
0
0
20
195
1.03
0.00
2.0
2.1
—
—
—
0
0
7
77
0.91
0.00
1.6
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.0
—
396.80
—
0
5
5
56
0.89
-0.00
1.2
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
56
0.89
-0.00
1.0
1.7
7.02
3.66
mg/l
—
5
56
5
56
0.89
-0.00
2.4
1.6
0.98
1.01
g/l
—
5
56
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
69
1.01
-0.00
1.1
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_SCNDPOLYCYTHAEMIA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_SCNDPOLYCYTHAEMIA | 2.337 [1.94, 2.81] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.556 |
During the follow-up period (1.1.1998 — 31.12.2019), 330 out of 1298 females with D3_SCNDPOLYCYTHAEMIA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_SCNDPOLYCYTHAEMIA | 1.929 [1.65, 2.25] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 574 out of 2522 males with D3_SCNDPOLYCYTHAEMIA died.
Mortality risk
Mortality risk for people of age
years, who have D3_SCNDPOLYCYTHAEMIA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.314% | 0.369% |
| 5 | 1.509% | 2.132% |
| 10 | 3.477% | 5.162% |
| 15 | 6.641% | 10.023% |
| 20 | 12.368% | 16.089% |
Relationships between endpoints
↥Index endpoint: D3_SCNDPOLYCYTHAEMIA – Secondary polycythaemia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data